Neurocrine Biosciences, Inc.

Headquarters: San Diego, CA, United States

Founded: 1992

Employees: 900

CEO: Dr. Kevin C. Gorman Ph.D.


Market Cap

$13.12 Billion

USD as of Jan. 1, 2024

history Market Cap History

Neurocrine Biosciences, Inc. market capitalization over time

Evolution of Neurocrine Biosciences, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Neurocrine Biosciences, Inc.

Detailed Description

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Top 1-year algo backtest: +240.10%

$10,000 in February 2023 would now be $34,010 by following it 5 minutes per day at market close.

How much did you gain in the last 12 months?

Stocks & Indices

Neurocrine Biosciences, Inc. has the following listings and related stock indices.

Stock: NASDAQ: NBIX wb_incandescent

Stock: Bovespa: N1BI34 wb_incandescent

Stock: FSX: NB3 wb_incandescent

Key People

William Rastetter, Chairman Kevin C. Gorman, CEO


Revenue: $788 Million(2019)



12780 El Camino Real

San Diego, CA 92130

United States

Phone: 858-617-7600